GLP-1 Evidence

Úsáidí eile

Drugaí GLP-1: duáin, ae, apnoea codlata, andúil

Tá cuid de na torthaí neamh-choimeádta chomh láidir le na sonraí meáchain. Tá daoine eile ina thrialacha beaga amháin agus i bhfad de dhóchas. Seo é atá i gceist.

Updated 4 min read 24 citations Evidence strength 3/5

Binse saotharlainne ceimice le gloine agus buidéil réagán in áit
Cjp24 · CC BY-SA 3.0 · Wikimedia Commons

Duáin: an cás neamh-choimeádta is láidre

Léiríodh i meata-anailís 2025 ar thrialacha randamacha torthaí duáin agus galar croí le chéile agus fuair sé sochar comhoiriúnach [1]. I gcás daoine atá ag fulaingt cheana le galar duáin chróin, shroich athbhreithniú córasach dírithe an chonclúid chéanna [2]. Bhí anailísí roimhe seo tar éis an comhartha duáin a chur in iúl in éineacht leis an gcomhartha croí [5][10], agus léirigh tirzepatide sochar duáin i gcoinne insulin glargine i gcruthúnas SURPASS-4 [7].

Tá an gaol idir obezity agus galar duáin féin go maith comhoiriúnaithe [9], mar sin tá cosán a ghabhann le meáchan plauis. — ach mar atá le torthaí croí, ní féidir le na trialacha difear díreach a scaradh ó na héifeachtaí a ghabhann le meáchan.

Sochar torthaí duáin

Ae: isteach sa treoirlínte

Is é an galar ae a bhaineann le dysfunction meitibileach an réimse ina bhfuil úsáid neamh-choimeádta tar éis dul ar aghaidh go tapa ó thrialacha go cleachtas. Laghdóidh tirzepatide ábhar saill ae agus tógáil adipose abdominal i gcoinne insulin degludec i gcomparáid randamach [6], agus tá fianaise leordhóthanach ag semaglutide chun a bheith i láthair i dtreoirlínte bainistíochta oifigiúla na hEorpa. Cuireann meata-anailís líonra na cóireálacha drugaí diaibéiteas an rang seo go fabhrach ar an gcoibhneas sochar-díobháil níos leithne [4].

Laghduithe ar saill ae

Apnoea codlata

Clúdaithe go hiomlán ar an leathanach tirzepatide: tháinig trial randamach tiomnaithe i gcás apnoea codlata obstructive measartha go trom le obezity ar tháinig laghdú suntasach ar an innéacs apnoea-hypopnoea. Is é seo an chéad druga le fianaise randamach i gcás a bhí ar a shon féin ag CPAP agus máinliacht.

Andúil: an ceann suimiúil, agus an laige

Tá an scéal meicniúil tarraingteach. Tá gabhdóirí GLP-1 i láthair i gcóras duais an inchinn, laghdaíonn na drugaí gníomh na hiontrála bia, agus tuairiscíonn úsáideoirí go spontáineach go n-ólann siad alcól níos lú. Má tá comhartha GLP-1 ag modhnú duais go ginearálta seachas duais bia go sonrach, bheadh éifeachtaí ar iompar andúil eile.

Níor ghabh an fianaise dhaonna suas. Níor tháinig trial randamach rialaithe le placebo ar exenatide i gconradh úsáid alcóil le toradh dearfach glan ar an gcríoch tosaigh, cé go raibh comharthaí le feiceáil i ngrúpaí fo-chórais agus críochfoirt íomhá [8]. Is é sin bonn réasúnta le haghaidh tuilleadh trialacha agus bonn bocht le haghaidh oideas.

Andúil agus úsáid substaintí

Cad atáimid ag iarraidh gan clúdach go fóill

Tá deimhneacht néareolaíoch, galar ovarach polcystic, athlasadh chróin agus riosca ailse go léir ag baint le cláir trial gníomhacha agus go praiticiúil níl aon fianaise randamach críochnaithe sna daonraí atá á plé ar líne. Nuair a thuairiscíonn na trialacha sin, beidh an leathanach seo ag athrú. Go dtí sin, tá sé go díreach an botún a dhéanann scríbhneoireacht sláinte neamhiontaofa a chóireáil mar atá bunaithe.

Ceisteanna coitianta

An gcabhróidh sé le m'ól?
B'fhéidir, ach níor léirigh an t-aon triail randamaithe amháin tairbhe shoiléir ar a príomh-chríochphointe [8]. Tá scéal aonair chun tosaigh ar fhianaise faoi láthair.
An féidir liom é a thógáil chun na duáin a chosaint?
Tá an fhianaise maidir leis na duáin láidir [1][2] agus tá sé seo ag éirí ina chuid níos mó de threoirlínte cliniciúla i ndiaibéiteas agus i ngalar cróineach duáin. Is comhrá é seo le bheith agat le speisialtóir duán.
An laghdaíonn sé athlasadh?
Feabhsaíonn marcóirí athlasta, ach táthar ag súil leis sin le cailliúint mheáchain shuntasach agus ní shuíonn sé ann féin tairbhe chliniciúil.
An bhfuil sé úsáideach le haghaidh PCOS?
Cuidíonn cailliúint mheáchain le PCOS, agus is cúis le cailliúint mheáchain iad na drugaí seo. Tá fianaise randamaithe thiomnaithe le críochphointí sonracha PCOS teoranta.
Peann instealladh inslin grianghraf ar a fhad ar chúlra buí
Wesalius · CC BY 4.0 · Wikimedia Commons
An cruthúnas atá taobh thiar den leathanach seo Bar dhíreach a thaispeánann comhoibriú na 12 foilsitheachta a luaitear ar an leathanach seo de réir cineál staidéir. 6411meta-analysis (6)randomised trial (4)review (1)other (1)
12 foils, 2019–2025. Is é sin meascán le trialacha agus sintéis ann, atá mar an suíomh óna bhfuil éileamh faoi chúis réasúnta. Téarma: liosta luaiteanna féin an leathanach seo, thíos.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis Peng TR, Lin HH, Tseng TL, et al. · British journal of clinical pharmacology · 2026 · Meta-analysis DOIPubMed 42273973Full text
  2. Beyond Monotherapy: The Superior Efficacy of Combined GLP-1 Receptor Agonist and SGLT2 Inhibitors on Renal Biomarkers: A Systematic Review and Meta-Analysis AbdelMagid AM, Kamel AM, Farid SF · Pharmacotherapy · 2026 · Meta-analysis DOIPubMed 41947610
  3. Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials Zhao S, Tian F, Yu L, et al. · Internal and emergency medicine · 2026 · Meta-analysis DOIPubMed 41917519
  4. Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis Elganyny MKE, Elganyni AKE, Maskji HA, et al. · La Clinica terapeutica · 2026 · Meta-analysis DOIPubMed 42340790
  5. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes Natale P, Green SC, Tunnicliffe DJ, et al. · The Cochrane database of systematic reviews · 2025 · Meta-analysis DOIPubMed 39963952Full text
  6. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials Badve SV, Bilal A, Lee MMY, et al. · The lancet. Diabetes & endocrinology · 2025 · Meta-analysis DOIPubMed 39608381
  7. Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials Chen JY, Hsu TW, Liu JH, et al. · American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025 · Meta-analysis DOIPubMed 39863261
  8. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials Apperloo EM, Neuen BL, Fletcher RA, et al. · The lancet. Diabetes & endocrinology · 2024 · Meta-analysis DOIPubMed 38991584
  9. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Shi Q, Nong K, Vandvik PO, et al. · BMJ (Clinical research ed.) · 2023 · Meta-analysis DOIPubMed 37024129Full text
  10. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease Zhang Y, Jiang L, Wang J, et al. · Cardiovascular diabetology · 2022 · Meta-analysis DOIPubMed 36335326Full text
  11. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis Yamada T, Wakabayashi M, Bhalla A, et al. · Cardiovascular diabetology · 2021 · Meta-analysis DOIPubMed 33413348Full text
  12. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Kristensen SL, Rørth R, Jhund PS, et al. · The lancet. Diabetes & endocrinology · 2019 · Meta-analysis DOIPubMed 31422062
  13. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study Harrison SA, Frias JP, Lucas KJ, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025 · Randomised controlled trial DOIPubMed 38447814
  14. Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight Malhotra A, Grunstein RR, Azarbarzin A, et al. · Sleep medicine · 2025 · Randomised controlled trial DOIPubMed 41135142Full text
  15. Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial) Agarwal R, Green JB, Heerspink HJL, et al. · Diabetes care · 2025 · Randomised controlled trial DOIPubMed 40968755Full text
  16. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Gastaldelli A, Cusi K, Fernández Landó L, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35468325
  17. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial Heerspink HJL, Sattar N, Pavo I, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 36152639
  18. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial Klausen MK, Jensen ME, Møller M, et al. · JCI insight · 2022 · Randomised controlled trial DOIPubMed 36066977Full text
  19. [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes] Scheen AJ, Radermecker RP, Paquot N · Revue medicale suisse · 2022 · Randomised controlled trial DOIPubMed 36004653
  20. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes Gerstein HC, Sattar N, Rosenstock J, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 34215025
  21. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes Hartman ML, Sanyal AJ, Loomba R, et al. · Diabetes care · 2020 · Randomised controlled trial DOIPubMed 32291277Full text
  22. Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH) Van Kleef LA, Michel M, Alkhouri N, et al. · Drug design, development and therapy · 2026 · Review DOIPubMed 41868171Full text
  23. Chronic Kidney Disease and Obesity Hojs R, Ekart R, Bevc S, et al. · Nephron · 2023 · Review DOIPubMed 37271131
  24. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Sattar N, Lee MMY, Kristensen SL, et al. · The lancet. Diabetes & endocrinology · 2021 · Journal article DOIPubMed 34425083

This page was translated automatically from English. The citations and numbers are unchanged. Read the English original if anything reads oddly. Read the English original